Heart Surgery News and Research

RSS

Heart surgery is done to correct problems with the heart. More than half a million heart surgeries are done each year in the United States for a variety of heart problems. Heart surgery is used to correct heart problems in children and adults. This article discusses heart surgeries for adults. For more information about heart surgeries for children, see the Diseases and Conditions Index articles on congenital heart defects, holes in the heart, and tetralogy of Fallot.

The most common type of heart surgery for adults is coronary artery bypass grafting (CABG). During CABG, surgeons use healthy arteries or veins taken from another part of the body to bypass (that is, go around) blocked arteries. CABG relieves chest pain and reduces the risk of heart attack.

Gagnon Cardiovascular Institute adopt new medical device to treat patients with severe aortic stenosis

The Gagnon Cardiovascular Institute at Morristown Medical Center today became the first hospital in the tri-state area to adopt a new minimally invasive medical device to treat patients with severe aortic stenosis who are too ill or frail to have their aortic valves replaced trough traditional open-heart surgery.

25 Jan 2014

BIDMC receives FDA approval to use new medical device in patients with severely damaged aortic heart valves

Beth Israel Deaconess Medical Center (BIDMC) yesterday became the first institution in the United States to use a new minimally invasive medical device since it received FDA approval last week.

From Medtronic 24 Jan 2014

MicroPort Scientific, Sorin Group form joint venture to market CRM devices in China

MicroPort Scientific Corporation and Sorin Group, announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest.

9 Jan 2014

Bio-inspired biodegradable surgical glue repairs defects of heart and blood vessels

Gecko Biomedical, a French medical device company developing 'bio-inspired' biodegradable surgical glues and patches for wound closure, announces that the Company's co-founders have published data demonstrating the potential of its paradigm-shifting technologies for minimally invasive reconstructive heart surgery.

9 Jan 2014

Bio-inspired adhesive may help surgeons treat congenital heart defects, other heart problems

When a child is born with a heart defect such as a hole in the heart, the highly invasive therapies are challenging due to an inability to quickly and safely secure devices inside the heart.

9 Jan 2014

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

Oxygen Biotherapeutics, Inc. ("OBI") a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on ClinicalTrials.gov, "Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass."

7 Jan 2014

New technology could dramatically reduce number of open-heart surgeries

Researchers at the University of Waterloo have developed a new technology that could dramatically reduce the number of open-heart surgeries for people with pacemakers.

18 Dec 2013

INTENSIA family of ICDs and CRT-D devices receive CE mark approval

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that the INTENSIA family of implantable cardioverter defibrillators and cardiac resynchronization therapy devices received CE (Conformité Européenne) mark approval. This family of devices includes the single-chamber INTENSIA VR, the dual-chamber INTENSIA DR and the INTENSIA SonR® CRT-D devices, all of which feature a DF-4 high voltage connector.

6 Dec 2013

U.S. physicians use CSI's Diamondback 360 Coronary OAS for coronary artery disease treatment

Cardiovascular Systems, Inc., today announced that its new Diamondback 360 Coronary Orbital Atherectomy System is being used by physicians across the country to treat coronary artery disease. This follows the company's recent PMA approval from the U.S. Food and Drug Administration to market the device as a treatment for severely calcified coronary arteries.

3 Dec 2013

Nearly 1% of all newborns in Switzerland diagnosed with congenital heart defect

Approximately one percent of all newborns in Switzerland are diagnosed with a congenital heart defect, roughly half of them require open heart surgery. Most children, including those with the most severe heart defects, survive because of the significant advancements in surgical techniques. Therefore, the current research focuses less on survival than on long-term consequences and quality of life of these children.

2 Dec 2013

Sorin Group receives CE Mark approval for Solo Smart stentless aortic valve

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that it has received CE Mark approval for the Solo Smart stentless aortic valve.

23 Nov 2013

Many primary care pediatricians feel uncomfortable in providing care to patients with genetic disorders

Many primary care pediatricians say they feel uncomfortable providing health care to patients with genetic disorders. Also, many do not consistently discuss all risks and benefits of genetic tests with patients, according to research published today in the American Journal of Medical Genetics.

20 Nov 2013

MICS CABG procedure safe and feasible, confirms new study

A new study published by The Journal of Thoracic and Cardiovascular Surgery confirms MICS CABG (minimally invasive cardiac surgery/coronary artery bypass grafting) is a safe and feasible procedure that ensures positive outcomes. Published on Nov 1st, the article brings light to the open-heart surgery alternative pioneered by Medical Director and cardiothoracic surgeon, Joseph T. McGinn of The Heart Institute at Staten Island University Hospital.

20 Nov 2013

U-M researchers collaborate with MDCH to evaluate statewide influenza vaccination reminder campaign

A new University of Michigan study found that the state immunization registry - the public health database that tracks vaccinations- can be an effective tool to encourage influenza vaccinations during a pandemic.

19 Nov 2013

New procedure repairs the mitral valve in patients at high risk for open heart surgery

A minimally invasive procedure is the first effective treatment for patients who are high risk for standard open heart surgery for a leaking heart valve, a study led by a University of Virginia School of Medicine researcher has found.

14 Nov 2013

New biosensor could help doctors devise new ways to minimize brain damage during heart surgery

Johns Hopkins engineers and cardiology experts have teamed up to develop a fingernail-sized biosensor that could alert doctors when serious brain injury occurs during heart surgery. By doing so, the device could help doctors devise new ways to minimize brain damage or begin treatment more quickly.

11 Nov 2013

Cycling champion Cadel Evans takes part in cutting edge cardiopulmonary research

As the first Australian to win the Tour de France, cycling champion Cadel Evans has already pedalled his way into our hearts. Now he is taking part in world-leading cardiopulmonary research – by pedalling inside an MRI scanner.

11 Nov 2013

Landmark clinical trial of artificial aortic heart valve shows positive results

Loyola University Medical Center is the only Chicago hospital participating in a landmark clinical trial of an artificial aortic heart valve that does not require open heart surgery.

From Medtronic 8 Nov 2013

Current percutaneous techniques shed light on treatment of heart valve leakage

A Paravalvular regurgitation, or leakage, commonly affects valvular prostheses, particularly artificial valves placed percutaneously according to data presented at the 2013 Transcatheter Cardiovascular Therapeutics (TCT) conference.

4 Nov 2013

Multi-center study finds causes for neonatal mortality in infants with HLHS

A first-of-its-kind study led by Texas Children's Hospital and Baylor College of Medicine, published online in the journal, Circulation, found that infants with hypoplastic left heart syndrome born far from a hospital providing neonatal cardiac surgery for HLHS have increased neonatal mortality, with most deaths occurring before surgery.

24 Oct 2013

Heart Surgery News and Research

Gagnon Cardiovascular Institute adopt new medical device to treat patients with severe aortic stenosis

BIDMC receives FDA approval to use new medical device in patients with severely damaged aortic heart valves

MicroPort Scientific, Sorin Group form joint venture to market CRM devices in China

Bio-inspired biodegradable surgical glue repairs defects of heart and blood vessels

Bio-inspired adhesive may help surgeons treat congenital heart defects, other heart problems

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

New technology could dramatically reduce number of open-heart surgeries

INTENSIA family of ICDs and CRT-D devices receive CE mark approval

U.S. physicians use CSI's Diamondback 360 Coronary OAS for coronary artery disease treatment

Nearly 1% of all newborns in Switzerland diagnosed with congenital heart defect

Sorin Group receives CE Mark approval for Solo Smart stentless aortic valve

Many primary care pediatricians feel uncomfortable in providing care to patients with genetic disorders

MICS CABG procedure safe and feasible, confirms new study

U-M researchers collaborate with MDCH to evaluate statewide influenza vaccination reminder campaign

New procedure repairs the mitral valve in patients at high risk for open heart surgery

New biosensor could help doctors devise new ways to minimize brain damage during heart surgery

Cycling champion Cadel Evans takes part in cutting edge cardiopulmonary research

Landmark clinical trial of artificial aortic heart valve shows positive results

Current percutaneous techniques shed light on treatment of heart valve leakage

Multi-center study finds causes for neonatal mortality in infants with HLHS

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News